Economic Update

Debate between Mike Wood and Jeremy Hunt

Monday 17th October 2022 Commons Chamber

[Mike Wood (Dudley South) (Con)]

I know the Chancellor will not have taken the decisions that he has today easily, but he will recognise that the planned increases in alcohol duties will have a devastating impact on many small pubs, small brewers and hospitality businesses. Will he look at how the changes he is making to beer duty in particular can be structured to help rather than harm small hospitality businesses, and perhaps bring forward the implementation of draught beer duty?

[Jeremy Hunt]

I hear my hon. Friend. The hospitality industry is incredibly important to our economy. I have two things to say. As he knows, we are reviewing the whole structure of alcohol duties, and as part of that process we will be keeping the levels of duty under constant review.

Oral Answers to Questions

Debate between Mike Wood and Jeremy Hunt

Tuesday 26th February 2019 Commons Chamber

[Mike Wood (Dudley South) (Con)]

22. What steps his Department is taking to help tackle the persecution of Christians overseas.

[The Secretary of State for Foreign and Commonwealth Affairs (Mr Jeremy Hunt)]

The UK has long championed freedom of religion, but I am concerned that we could do more for the 240 million Christians estimated to be facing persecution for their faith around the world. I have therefore asked the Bishop of Truro to conduct an independent review into what more the FCO can do. Last week, I agreed the terms of reference for his review.

--- Later in debate ---

[Mr Hunt]

We do all we can to raise these issues. I raised freedom of religion issues with my counterpart, Foreign Minister Wang Yi, when I went to China last August. We raised them in November in the Universal Periodic Review—a regular review of human rights issues in China. The noble Lord Ahmad is in Geneva this week for the UN Human Rights Council, where he will also be raising the issue of freedom of religion in China. My hon. Friend is right to be concerned.

[Mike Wood]

It was reassuring to see the Pakistan Government protecting the independence of their courts in overturning the blasphemy conviction against Asia Bibi. What support are this Government giving the new Government in Pakistan to ensure consistent protection of Christians from persecution?

[Mr Hunt]

We have excellent relations with the new Government of Pakistan; in fact, I spoke to the Pakistani Foreign Minister yesterday. We co-operated on the Asia Bibi issue. We wanted to support them because we recognise that the situation on the ground there is extremely fragile. They are trying to do the right thing. As one of the biggest aid donors to Pakistan, we play a crucial role in stiffening their resolve to do the right thing.

Health Service Medical Supplies (Costs) Bill

Debate between Mike Wood and Jeremy Hunt

2nd reading: House of Commons & Programme motion: House of Commons
Monday 24th October 2016 Commons Chamber

[Mike Wood (Dudley South) (Con)]

Has my right hon. Friend made any assessment of how the prices of the drugs quoted in the article in The Times compare with those paid in other health services and by healthcare providers in other western European countries?

[Mr Hunt]

We have made some assessments of those things, but, in essence, our concern is that, even without comparisons with what is happening in other countries, we are talking about totally unreasonable behaviour. I mentioned one example earlier, but I can give another of a medicine whose price increased by 3,600% between 2011 and 2016. I just do not think we can justify that. Given that we want to have strong, harmonious, positive relationships between the NHS and the pharmaceutical industry, we need to eliminate the possibility of that kind of behaviour happening in the future.

This Bill therefore amends the 2006 Act to allow the Government to control prices of these medicines, even when the manufacturer is a member of the voluntary PPRS scheme. We intend to use the power only where there is no competition in the market and companies are charging the NHS an unreasonably high price. We will engage with the industry representative body, which is also keen to address this practice, on how we will exercise this power.

The final element of the Bill will strengthen the Government’s powers to collect information on the costs of medicines, medical supplies and other related products from across the supply chain, from factory gate to those who supply medicines to patients. We currently collect information on the sale and purchases of medicines from various parts of the supply chain under a range of different arrangements and for a range of specific purposes. Some of these arrangements are voluntary, whereas others are statutory. The Bill will streamline the existing information requirements in the 2006 Act relating to controlling the cost of healthcare products. It will enable the Government to make regulations to require all those involved in the manufacture, distribution or supply of health service medicines, medical supplies or other related products to record, keep and provide on request information on sales and purchases. The use of this information would be for defined purposes: the reimbursement of community pharmacies and GPs, determining the value for money that the supply chain or products provide; and controlling the cost of medicines. This will enable the Government to put the current voluntary arrangements for data provision with manufacturers and wholesalers of unbranded generic medicines and manufactured specials on a statutory footing. As the arrangements are currently voluntary, they do not cover all products and companies, which limits the robustness of the reimbursement price setting mechanism.

A statutory footing for these data collections is important so that the Government can run a robust reimbursement system for community pharmacies. I know that some colleagues have raised concerns about the implications of our funding decisions for community pharmacies, and today I want to reassure the House that this Bill does not impact on those decisions, nor does it remove the requirement for consultation with the representative body of pharmacy contractors on their funding arrangements in the future. However, the information power will give us more data on which to base those discussions and decisions, rather than relying on data only available to us under voluntary schemes and arrangements. The information power would also enable the Government to obtain information from across the supply chain to assure themselves that the supply chain is, or parts of it are, delivering value for money for NHS patients and the taxpayer—we cannot do that with our existing fragmented data.

Junior Doctors: Industrial Action

Debate between Mike Wood and Jeremy Hunt

Monday 5th September 2016 Commons Chamber

[Mr Hunt]

Yes, I can absolutely confirm that. We have put in place pay protection to make that happen. My hon. Friend is right that this is very damaging for his constituents in Cheltenham. Given that there is so much pressure in the NHS, the junior doctors who are thinking of striking must ask themselves whether it is really going to help their organisation respond to those pressures if it has this enormous distraction—this incredible demoralisation that we get with these kinds of strikes.

[Mike Wood (Dudley South) (Con)]

Does my right hon. Friend share my disappointment that the BMA leader who co-authored the new contract and said that it was beneficial for our patients and for our junior doctors is now trying to whip up support for a series of strikes that every credible medical leader has said would be disproportionate and harmful to patients?

[Mr Hunt]

I am extremely disappointed and I hope that she reconsiders.

Oral Answers to Questions

Debate between Mike Wood and Jeremy Hunt

Tuesday 13th October 2015 Commons Chamber

[Mike Wood (Dudley South) (Con)]

6. What plans his Department has to increase capacity in general practice and primary care.

[The Secretary of State for Health (Mr Jeremy Hunt)]

It is a pleasure to be back, Mr Speaker. By 2020, we will increase the primary and community care workforce by at least 10,000, including an estimated 5,000 doctors working in general practice, as well as more practice nurses, district nurses and pharmacists.

[Mr Hunt]

My hon. Friend is right, regrettably, that the PFI projects under the previous Labour Government created a lot of unsustainable debt. I know her local clinical commissioning group is meeting GP practices and working with community health partnerships to see if they can progress the idea she is campaigning for. I hope to visit her in the near future to discuss it myself.

[Mike Wood]

Will my right hon. Friend join me in welcoming the £2.7 million in vanguard funding given to Dudley to provide primary care services out in the community? This will not only improve the level of clinical and social services provided to people in Dudley South, but relieve pressures on Russells Hall hospital.

[Mr Hunt]

I welcome my hon. Friend to his post. I am not sure I have had a question from him before. I know quite a bit about the Dudley vanguard programme, because I shared a taxi to Manchester station with the entire Dudley team. They told me, at close quarters, about their exciting plans. What really struck me was how they are talking to different bits of the health and social care system in a way that has never happened before. It is really exciting and I think it really will be in the vanguard of what can happen in the NHS.